108 related articles for article (PubMed ID: 24925351)
1. NO147: the Giving Tree.
Leichman L
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24925351
[No Abstract] [Full Text] [Related]
2. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.
Fearon ER; Carethers JM
Gastroenterology; 2015 Jan; 148(1):10-3. PubMed ID: 25451650
[No Abstract] [Full Text] [Related]
3. Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type disease.
Faris JE; Ryan DP
J Clin Oncol; 2012 Apr; 30(12):1255-7. PubMed ID: 22393091
[No Abstract] [Full Text] [Related]
4. [Ways of handling surgical material from patients with colon cancer - standard and additional highly specialized research with colorectal cancer].
Nasierowska-Guttmejer A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S40-50. PubMed ID: 26165033
[No Abstract] [Full Text] [Related]
5. [Examination of molecular markers used n the treatment of colon cancer].
Domagała P; Kowalik A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
[No Abstract] [Full Text] [Related]
6. BRAF: a driver of the serrated pathway in colon cancer.
Rustgi AK
Cancer Cell; 2013 Jul; 24(1):1-2. PubMed ID: 23845435
[TBL] [Abstract][Full Text] [Related]
7. Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?
Sinicrope FA; Shi Q
J Natl Cancer Inst; 2012 Nov; 104(21):1616-8. PubMed ID: 23104213
[No Abstract] [Full Text] [Related]
8. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
Andrews MC; Behren A; Chionh F; Mariadason J; Vella LJ; Do H; Dobrovic A; Tebbutt N; Cebon J
J Clin Oncol; 2013 Dec; 31(35):e448-51. PubMed ID: 24190114
[No Abstract] [Full Text] [Related]
9. From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS.
Vauthey JN; Kopetz SE
Cancer; 2013 Dec; 119(23):4083-5. PubMed ID: 24105015
[No Abstract] [Full Text] [Related]
10. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.
Symvoulakis EK; Zaravinos A; Zoras O; Spandidos DA
Int J Biol Markers; 2011; 26(4):276-7. PubMed ID: 22139644
[No Abstract] [Full Text] [Related]
12. Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms.
Li VS; Yuen ST; Chan TL; Yan HH; Law WL; Yeung BH; Chan AS; Tsui WY; So S; Chen X; Leung SY
Gastroenterology; 2009 Jul; 137(1):176-87. PubMed ID: 19303019
[TBL] [Abstract][Full Text] [Related]
13. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
[No Abstract] [Full Text] [Related]
14. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
[TBL] [Abstract][Full Text] [Related]
16. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
Bass A
J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
[No Abstract] [Full Text] [Related]
17. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
18. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
19. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
20. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
